Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garadacimab prophylaxis study in hereditary angioedema
2020-000570-25Phase 3Completed
- Sponsor
- CSL Behring
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hereditary angioedema (HAE) comparing Garadacimab with Placebo (2 arms). Primary endpoint: Time-normalized number of hereditary angioedema attacks during treatment period. Started Sep 2020; status: completed.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2020-000570-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000570-25.